Home versus in-patient treatment for deep vein thrombosis

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 1, 2018, Pages

  Othieno, Richard ^a   Okpo, Emmanuel ^b   Forster, Rachel ^c  

^a NHS LOTHIAN   (United Kingdom)

^b NHS GRAMPIAN   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; FIBRINOLYTIC AGENT;

ARTICLE; BLEEDING; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; ECONOMIC EVALUATION; FOLLOW UP; HOME CARE; HOSPITAL CARE; HOSPITAL PATIENT; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; MORTALITY; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CHEMICALLY INDUCED; COST BENEFIT ANALYSIS; FIBRINOLYTIC THERAPY; HOSPITALIZATION; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; STANDARDS; VEIN THROMBOSIS;

COST-BENEFIT ANALYSIS; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HOME CARE SERVICES; HOSPITALIZATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SECONDARY PREVENTION; THROMBOLYTIC THERAPY; VENOUS THROMBOSIS;

EID: 85041600749     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003076.pub3     Document Type: Article

References (71)

1. Bäckman K, Carlsson P, Kentson M, Hansen S, Engquist L, Hallert C. Deep venous thrombosis: a new task for primary health care. Scandinavian Journal of Primary Health Care 2004;22(1):44-9
2. Boccalon H, Elias A, Chale JJ, Cadene A, Dumoulin A. Treatment of deep vein thrombosis at home: from theory to medical practice [French]. Bulletin de l'Academie Nationale de Medecine 1998;182(1):101-15
3. Boccalon H, Elias A, Chale JJ, Cadene A, Gabriel S. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecularweight heparin: the Vascular Midi-Pyrenees study. Archives of Internal Medicine 2000;160(12):1769-73
4. Chong BH. A randomized, prospective, multicentre study comparing the efficacy, safety and cost of once-daily enoxaparin given at home with unfractionated heparin given in hospital in the treatment of deep-vein thrombosis. Blood 2002;100(11):Abstract 2772
5. Chong BH, Brighton TA, Baker RI, Thurlow P, Lee CH, ASTH DS Group. Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis. Journal of Thrombosis and Thrombolysis 2005;19(3):173-81
6. Daskalopoulos ME, Daskalopoulou SS, Tzortzis E, Sfiridis P, Nikolaou A, Dimitroulis D, et al. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. European Journal of Vascular and Endovascular Surgery 2005; 29(6):638-50
7. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, et al. Treatment of patients with venous thrombosis with intravenous unfractionated heparin in hospital compared with subcutaneous lowmolecular-weight heparin out of hospital. Annals of Hematology 1996;72:A3
8. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin in hospital as compared with subcutaneous low molecular weight heparin at home. New England Journal of Medicine 1996;334(11):682-7
9. van den Belt AGM, Bossuyt PMM, Prins MH, Gallus AS, Buller HR. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis-an economic evaluation. Thrombosis and Haemostasis 1998;79:259-62
10. Levine M, Gent M, Hirsch J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. New England Journal of Medicine 1996;334: 677-82
11. O'Brien B, Levine M, Willan A, Goeree R, Haley S, Blackhouse G, et al. Economic evaluation of outpatient treatment with low-molecular-weight-heparin for proximal vein thrombosis. Archives of Internal Medicine 1999;159: 2298-304
12. Ramacciotti E, Araujo GR, Lastoria S, Dietrich F, Maffei FH, Mussi NS. The efficacy and safety of enoxaparin oncedaily given partly at home, compared with unfractionated heparin given in the hospital in the treatment of proximal deep-vein thrombosis, a Brazilian multicenter study. Blood 2001;98(11):Abstract 4026
13. Ramacciotti E, Araujo GR, Lastoria S, Maffei FH, Dietrich F. An open-label, comparative study of the efficacy and safety of an outpatient single daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. Blood 2002;11:503a-Abstract 1960
14. Ramacciotti E, Araujo GR, Lastoria S, Maffei FH, Dietrich-Neto F, CLETRAT Investigators. Efficacy and safety of once-daily enoxaparin given in the outpatient setting compared with in-hospital unfractionated heparin for treatment of proximal lower limb deep-vein thrombosis. Journal of Thrombosis and Haemostasis 2003;1(Suppl 1): Abstract P1401
15. Ramacciotti E, Araujo GR, Lastoria S, Maffei FH, Karaoglan DM, Michaelis W, et al. An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. Thrombosis Research 2004;114(3):149-53
16. Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, EgloffM, et al. An international, randomized noninferiority trial of outpatient versus inpatient treatment for pulmonary embolism. Journal of General Internal Medicine 2011;26(10):1220
17. Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, EgloffM, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011;378(9785):41-8
18. Belcaro G, Nicolaides AN, Cesarone MR, Laurora G, De Sanctis MT, Incandela L, et al. Comparison of low molecular weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis. Angiology 1999;50(10):781-7
19. Blattler W, BorerW, Linder C. Outpatient and conventional treatment of acute deep vein thrombosis evaluated in a controlled single-centre study. Phlébologie 1998;51(1): 41-6
20. Blattler W, Borer W, Linder C, Bergan J. Outpatient and conventional treatment of acute deep vein thrombosis evaluated in a controlled single-centre study [Traitements ambulatoire et conventionnel de la thrombose veineuse profonde aigue: Bilan monocentrique]. Phlébologie 1998; 51(1):33-9
21. Buller H. Initial outpatient treatment of venous thromboembolism with Fondaparinux (Arixtra®): the MATISSE trials. Journal of Thrombosis and Haemostasis. 2005; Vol. 3, issue 1:Abstract P1112
22. Buller HR, The Matisse Investigators. Initial outpatient treatment of venous thromboembolism with fondaparinux (Arixtra(R)): the MATISSE trials. Blood. 104 2004; Vol. 104, issue 11:Abstract 705
23. Conner C. Innohep User's meeting, Windsor. Data on file 1999
24. Fitzmaurice DA, Hobbs FD, Murray ET, Holder RL, Allan TF, Rose PE. Oral anticoagulation management in primary care with the use of computerised decision support and near-patient testing: a randomised, controlled trial. Archives of Internal Medicine 2000;160(15):2343-8
25. Frank D, Blattler W. Comparison of ambulatory and inpatient treatment of acute deep venous thrombosis of the leg: subjective and economic aspects [German]. Schweizerische Medizinische Wochenschrift. Journal Suisse de Medecine 1998;128(36):1328-33
26. Goldhaber SZ, Morrison RB, Diran LL, Creager MA, Lee TH. Abbreviated hospitalisation for deep vein thrombosis with the use of ardeparin. Archives of Internal Medicine 1998;158(21):2325-8
27. Grau E, Real E, Pastor E, Viciano V, Aguilo J. Home treatment of deep vein thrombosis: a two-years experience of a single institution. Haematologica 1998;83(5):438-41
28. Grau E, Tenias JM, Real E, Medrano J, Ferrer R, Pastor E, et al. Home treatment of deep vein thrombosis with low molecular weight heparin: long-term incidence of recurrent venous thromboembolism. American Journal of Haematology 2001;67(1):10-4
29. Green ES, Rhodes S, Bond S, Thomson S, Troughton AH. Outpatient treatment of deep vein thrombosis using low molecular weight heparin. British Journal of Haematology 1998;101(Suppl 1):Abstract 234
30. Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs inhospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine 2000;160(14):2208-15
31. Hull RD, Pineo GF, Mah AF. Does rebound exist? A comparison of venous thromboembolic (VTE) event rates in the post-treatment period for patients randomized to long-term low-molecular-weight heparin (LMWH) versus warfarin sodium. Blood. 100 2002; Vol. 100, issue 11: Abstract 1951
32. Hull RD, Pineo GF, Brant R, Liang J, Cook R, Solymoss S, et al. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and postthrombotic syndrome. American Journal of Medicine 2009; 122(8):762-9
33. Lindmarker P, Holstrom M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group. Journal of Internal Medicine 1996; 240(6):395-401
34. Miles J, O'Shaugnessey D, Wimperis J. Outpatient management of DVT in the United Kingdom. Presentation to American Thoracic Society. 1998
35. Modesto-Alapont M, Nauffal-Manzur D, Nsotegui-Barrera E, Menendez-Villanueva R, Ballesta A, Touza R, et al. Can home prophylaxis for venous thromboembolism reduce mortality rates in patients with chronic obstructive pulmonary disease? [Spanish]. Archivos de Bronconeumologia 2006;42(3):130-4
36. O'Shaughnessy DF, Tovey C, Miller ALC, O'Neill V, Rana PS, Akbar S, et al. Outpatient management of deep vein thrombosis. Journal of Accident and Emergency Medicine 1998;15(5):292-3
37. Anon. Home treatment of pulmonary embolism. http://clinicaltrials.gov/show/NCT00214929. 2005
38. Otero R, Uresandi F, Jiménez D, Cabezudo MA, Oribe M, Nauffal D, et al. Home treatment in pulmonary embolism. Thrombosis Research 2010;126(1):e1-e5
39. Pineo GF, Hull RD, Mah AF, Lite I. Does rebound exist? A comparison of venous thromboembolic event rates in the post-treatment period for patients randomized to long-term low-molecular-weight heparin vs. warfarin sodium. Journal of Thrombosis and Haemostasis 2003;1(Suppl 1):Abstract P1882
40. Rymes NL, Lester W, Connor C, Chakrabati S, Fegan CD. Outpatient management of DVT using LMWH and a hospital outreach service. Clinical and Laboratory Haematology 2002;24(3):165-70
41. Ting SBN, Ziegenbein RW, Gan TE, Catalano JV, Monagle P, Silvers J, et al. Dalteparin for deep vein thrombosis: a hospital-in-the-home program. Medical Journal of Australia 1998;168(6):272-6
42. Wells PS, Kovacs MJ, Bormanis J, Forgie MA, Goudie D, Morrow B, et al. Expanding eligibility for outpatient treatment of deep vein thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Archives of Internal Medicine 1998;158(16):1809-12
43. White RH, McCurdy SA, von MarensdorffH, WoodruffDEJ, LeftgoffL. Home prothrombin time monitoring after the initiation of warfarin therapy. A randomised, prospective study. Annals of Internal Medicine 1989;111(9): 730-7
44. Wilson SJ, Wells PS, Kovacs MJ, Lewis GM, Martin J, Burton E, et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. Canadian Medical Association Journal 2003;169(4):293-8
45. Wimperis JZ, Pout G, Dilks G, Wilson P, Clarke J, Jenkins P, et al. Significant bed savings resulting from outpatient management of deep vein thrombosis with low molecular weight heparin. British Journal of Haematology 1998;101 (Suppl 1):Abstract 231
46. Ageno W, Grimwood R, Limbiati S, Dentali F, Steidl L, Wells PS. Home-treatment of deep vein thrombosis in patients with cancer. Haematologica 2005;90(2):220-4
47. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. GRADEWorking Group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328(7454):1490-4
48. Bakker M, Dekker PJ, Knot EA, van Bergen PF, Jonker JJ. Home treatment for deep venous thrombosis with low molecular weight heparin [letter]. Lancet 1988;2:1142
49. Baron RM, Goldhaber SZ. Deep venous thrombosis: early discharge strategies and outpatient management. Journal of Thrombosis and Thrombolysis 1999;7(2):113-22
50. East Lancashire Medicines Management Board. Use of Low Molecular Weight Heparins (LMWH) (e.g. Tinzaparin) in Primary Care: Best Practice Guideline. www.elmmb.nhs.uk/policies-and-guidelines/guidelines/(accessed 20 June 2017); Vol. Version 3
51. Erkens PMG, Prins MH. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database of Systematic Reviews 2010, Issue 9. [DOI: 10.1002/14651858.CD001100.pub3
52. Finks SW, Trujillo TC, Dobesh PP. Management of venous thromboembolism. Annals of Pharmacotherapy 2016;50(6): 486-501
53. McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 11 July 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015
54. Griffin J. Deep venous thrombosis and pulmonary embolism. London: Office of Health Economics, 1996
55. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org
56. Hyers TM, Spyropoulos AC, for the INNOVATE Investigators. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin. Journal of Thombosis and Thombolysis 2007; 24(3):225-32
57. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12
58. Leizorovicz A, Simmoneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep vein thrombosis: a meta-analysis. BMJ 1994;309: 299-304
59. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Archives of Internal Medicine 1995;155(6):601-7
60. National Institute for Health and Care Excellence (NICE). Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (CG144). www.nice.org.uk/guidance/CG144 (accessed 20 June 2017)
61. O'Brien B, Levine M, Willan A, Goeree R, Haley S, Blackhouse G, et al. Economic evaluation of outpatient treatment with low-molecular-weight-heparin for proximal vein thrombosis. Archives of Internal Medicine 1999;159: 2298-304
62. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014
63. Robertson L, Kesteven P, McCaslin JE. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. Cochrane Database of Systematic Reviews 2015, Issue 6. [DOI: 10.1002/14651858.CD010956.pub2
64. Robertson L, Jones LE. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database of Systematic Reviews 2017;Issue 2:Art. No.: CD001100
65. Ryan R, Hill S. How to GRADE the quality of the evidence. Cochrane Consumers and Communication Group, June 2016. Version 1.0. http://cccrg.cochrane.org/authorresources (accessed 13 August 2017)
66. van den Belt AGM, Bossuyt PMM, Prins MH, Gallus AS, Buller HR. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis-an economic evaluation. Thrombosis and Haemostasis 1998;79:259-62
67. van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014;124:1968-75
68. Wong M, Butt IL, on behalf of Wirral Drug and Therapeutics Committee. Low Molecular Weight Heparin Prescribing and Administration (Adults). http://mm.wirral.nhs.uk/document uploads/guidelines/LMWHprescribingandadministrationv1a.pdf. Version: v1a 2014 (accessed 13 July 2017)
69. Zelen M. A new design for randomized clinical trials. New England Journal of Medicine 1979;300:1242-5
70. Othieno R, Abu Affan M, Okpo E. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD003076.pub2
71. Schraibman IG, Milne AA, Royle EM. Home versus inpatient treatment for deep vein thrombosis. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: 10.1002/14651858.CD003076